Oramed Pharmaceuticals Inc.
ORMP
$3.65
$0.010.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 489.55% | 436.04% | 882.13% | -215.82% | -370.07% |
| Total Depreciation and Amortization | -27.54% | -37.31% | -43.26% | -34.10% | -22.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -972.59% | -1,193.31% | -290.97% | 141.24% | 206.79% |
| Change in Net Operating Assets | 583.88% | 87.63% | 96.85% | -187.92% | 189.86% |
| Cash from Operations | 18.31% | -8.71% | -33.73% | -962.57% | -68.03% |
| Capital Expenditure | 42.11% | 50.00% | -80.00% | 37.84% | 66.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -137.86% | -94.85% | -81.25% | -162.90% | 433.96% |
| Cash from Investing | -137.87% | -94.86% | -81.27% | -162.96% | 433.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 55.72% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -90.71% | -90.71% | -49.26% | -142,750.00% | -124,200.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.28% | 90.89% | 97.46% | -142,750.00% | -208.14% |
| Foreign Exchange rate Adjustments | -75.00% | -650.00% | 583.33% | 242.86% | 76.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -209.61% | -118.68% | -72.50% | -188.42% | 1,111.94% |